









Table 1.

D	m	F <sub>v</sub>	G	C	% <sub>v</sub>	R <sup>2</sup>	A <sub>v</sub>	R <sup>2</sup>	Partial-F	P <sub>unc</sub>	P <sub>perm</sub>	P <sub>emp</sub>													
													TH	DDC	VMAT2	DAT1	COMT	MAOA	MAOB	DRD1	DRD2	DRD3	TPH1	TPH2	SLC6A4
			TH	2	2	100	0.001	<0.001	0.712	0.491	0.484	0.485													
			DDC	47	6	90	0.010	0.006	2.329	0.031*	0.031*	0.038*													
			VMAT2	17	9	90	0.003	<0.001	0.501	0.875	0.878	0.862													
		/	DAT1	16	6	91	0.005	<0.001	1.027	0.406	0.408	0.466													
		C	COMT	18	6	91	0.012	0.009	2.648	0.015*	0.014*	0.027*													
			MAOA	6	3	90	0.003	<0.001	1.143	0.331	0.325	0.346													
			MAOB	37	5	92	0.005	0.002	1.367	0.234	0.232	0.293													
			DRD1	1	1	100	0.000	<0.001	0.097	0.756	0.756	0.780													
			DRD2	16	8	90	0.004	<0.001	0.721	0.673	0.680	0.770													
			DRD3	41	12	92	0.014	0.006	1.617	0.081	0.081	0.099													
			TPH1	2	2	100	0.001	<0.001	0.719	0.487	0.476	0.477													
			TPH2	6	4	93	0.002	<0.001	0.519	0.721	0.718	0.753													
			SLC6A4	8	3	90	0.006	0.004	2.795	0.039*	0.038*	0.037*													
			HTR1E	16	6	91	0.007	0.003	1.545	0.160	0.158	0.199													
			HTR2A	44	12	90	0.013	0.005	1.492	0.120	0.121	0.123													
			HTR2B	3	2	100	0.001	<0.001	0.596	0.551	0.551	0.519													
			HTR2C	22	8	90	0.006	<0.001	0.920	0.499	0.499	0.517													
			HTR3A	4	4	100	0.001	<0.001	0.364	0.834	0.831	0.833													
			HTR3B	22	6	90	0.001	<0.001	0.228	0.968	0.967	0.970													
			HTR3C	2	1	99	0.000	<0.001	0.124	0.725	0.724	0.677													
			HTR4	46	14	91	0.015	0.005	1.422	0.135	0.136	0.075													
			HTR5A	7	4	92	0.006	0.003	1.866	0.114	0.114	0.118													
			HTR6	2	1	100	0.000	<0.001	0.000	0.990	0.992	0.982													
			HTR7	22	6	93	0.006	0.002	1.316	0.247	0.242	0.301													
			HTRA1	34	9	91	0.007	<0.001	0.974	0.460	0.456	0.441													
			HTRA3	19	5	92	0.004	0.001	1.133	0.341	0.356	0.370													

C, m, %<sub>v</sub>, R<sup>2</sup>, A<sub>v</sub>, R<sup>2</sup>, Partial-F, P<sub>unc</sub>, P<sub>perm</sub>, P<sub>emp</sub>; \* P < 0.05.

Principle component analysis (PCA) was used to identify the principal components (PCs) that explain the maximum variance in the data. The first PC (PC1) explained 62% of the variance (F<sub>v</sub> = 0.62 ± 0.08%).

$$F_k, df(full) = \frac{RSS(reduced) - RSS(full)}{df(reduced) - df(full)} / \frac{RSS(full)}{df(full)} \quad (1)$$

Gene-behavior association results (COMT, SLC6A, DDC, MAOB; COMT: P = 0.028, SLC6A4: P = 0.029, MAOB: P = 0.070).

Gene-behavior association results (COMT, SLC6A, DDC, MAOB; COMT: P = 0.028, SLC6A4: P = 0.029, MAOB: P = 0.070).

Permutation tests

Permutation tests were used to assess the significance of the gene-behavior associations. The results showed that the associations with COMT, SLC6A4, and MAOB were significant (P = 0.028, P = 0.029, and P = 0.070, respectively).

Empirical tests

Empirical tests were used to assess the significance of the gene-behavior associations. The results showed that the associations with COMT, SLC6A4, and MAOB were significant (P = 0.028, P = 0.029, and P = 0.070, respectively).



MAOB  $R^2 = 0.028$ ,  $P = 0.043$ .

$-F = 2.499$ ,  $P = 0.031$ .  $(P = 0.038)$

MAOA

CA

SLC6A4

COMT

DDC

MAOB

I G

(COMT, SLC6A4, DDC MAOB)

G CA (F 1).

(H, 1975),

F 2

( ) . F COMT 4680

LD

4680, 165656 (1000G , 3, H C 75.1( 31410 1J0 -1.406 DB , )--337.4(C )--320.(CHB):

m 能 v 能  
DDC 能  
FC- m 能 v v .

MAOB 能 m m v v  
m 能 m

Bassett, K.L., & Bullmore, D. (2010). *Neuroimage*, 53(3), 804-9.

Bassett, D.S., & Bullmore, E. (2003). *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*, 117(1), 18-22.

Bassett, D.S., & Bullmore, E. (2006). *BMC Bioinformatics*, 7(1), 1.

Bassett, D.S., Bullmore, E., & Sporns, A. (2004). *BMC Bioinformatics*, 5(1), 1.

Cassidy, A., & Bullmore, E. (2008). *Source Code for Biology and Medicine*, 3, 15.

Cassidy, A., Bullmore, E., & Sporns, A. (2005). *Proceedings of the National Academy of Sciences of the United States of America*, 102(34), 12224-9.

Cassidy, A., Bullmore, E., & Sporns, A. (2012). *Management Science*, 58(1), 21-34.

Cassidy, A. (2001). *Heredity (Edinb)*, 87(1), 52-8.

Cassidy, A., & Bullmore, E. (2008). *Trends in Cognitive Sciences*, 12(1), 31-40.

Cassidy, A., Bullmore, E., & Sporns, A. (2010). *Journal of Psychiatric Research*, 44(11), 717-24.

Cassidy, A., & Bullmore, E. (2012). *Claremont McKenna College Robert Day School of Economics and Finance Research Paper (2012-01)*.

Cassidy, A., Bullmore, E., & Sporns, A. (2009). *Social Cognitive and Affective Neuroscience*, 4(4), 399-408.

H., D., K., J.L., C., et al. (2011). *Cognitive, Affective, & Behavioral Neuroscience*, 12(4), 678-91.

H., D., J.L., K., et al. (2011). (G A): *Neuroimage*, 56(4), 1875-91.

H., E., B., F., et al. (2004). B: *J Autism and Developmental Disorders*, 34(2), 229-35.

H., L. (2010). *Personality and Individual Differences*, 48(5), 649-53.

I., K., K., A., et al. (1999). *Neuroscience Letters*, 269(1), 37-40.

J., L., et al. (2014). (5-H L). *Neurobiology. Progress in Neurobiology*, 117, 41-53.

K., D., A. (1979). *Econometrica: Journal of the Econometric Society*, 263-91.

K., D., A. (1984). C, *American Psychologist*, 39(4), 341.

K., J., L., J., et al. (2006). F: *Movement Disorders*, 21(12), 2175-80.

K., C., L.G., et al. (2002). G: *Neurotoxicology* 23(4), 515-9.

K., A., K., H., J., et al. (2007). A: *Neuropsychobiology*, 56(56), 191-6.

K., B., G., J., et al. (2007). C, H 1B, *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*, 263-91.

, C.A., B , G.B., A , J., et al. (2007). C  
 (158) 5H L .  
 A H C . *Genes, Brain and Behavior*, **6**(7), 647-52.  
 , E., K , A , A. (2010). D  
*Progress in Neurobiology*, **92**(2), 112-33.  
 , A.L., J., , .E., ,  
 .A., , D. (2006). . *Nature Genetics*, **38**(8), 904-9.  
 , , B., -B , K., et al. (2007). LI K:  
*The American Journal of Human Genetics*, **81**(3),  
 559-75.  
 , D.E., C , B , et al. (2001). L .  
*Nature*, **411**(6834), 199-204.  
 , F , A., , A., , C. (2013).  
*Frontiers in Human Neuroscience*, **7**, 242.  
 , A., G , . (2003).  
*Proceedings of the National Academy of Sciences*, **100**(3),  
 1128-33.  
 , J., , B., , G.C., et al. (2009). A  
*Journal of Neuroscience*, **29**(18), 5985-91.  
 , J., D , C.J., H , E., G , K.D. (2009).  
 A ADHD -A  
*Journal of Autism & Developmental Disorders*, **39**(1), 67-74.  
 , D , B , A. (2005).  
*Clinical Neuropharmacology*, **28**(5), 228-37.  
 , E.E. (2009).  
*Nature*, **461**(7261), 218-23.  
 , D.J. (2004). E  
*Genetic Epidemiology*, **27**(4), 348-64.  
 , C., , H.H., , L. (2010).  
*Neuroimage*, **53**(3), 810-21.  
 , H., J., , A.I., H , A. (2003).  
*Psychological Science*, **14**(1), 7-13.  
 , E., , I., , L., et al. (2014). D  
*Proceedings of the National Academy of Sciences*,  
**111**(26), 9615-20.